Welcome to our dedicated page for OMNICELL SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OMNICELL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OMNICELL's regulatory disclosures and financial reporting.
Omnicell, Inc. executive reports routine share withholding for taxes. The company’s EVP and Chief Operating Officer reported the disposition of 4,095 shares of Omnicell common stock on 11/15/2025 at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes due on vesting of restricted stock units.
After this tax withholding, the executive beneficially owns 87,193 shares of Omnicell common stock. This balance includes an adjustment for 359 shares purchased under Omnicell’s Employee Stock Purchase Plan on 8/15/2025, as noted in the footnotes.
Omnicell, Inc. (OMCL) reported an equity award to its Executive Vice President & Chief Financial Officer, H. Baird Radford III, on a Form 4. On 11/15/2025, he received 32,932 shares of Omnicell common stock in the form of restricted stock units granted under the company’s equity incentive plan at a stated price of $0 per share, reflecting a stock-based award rather than a cash purchase. After this grant, he beneficially owns 32,932 shares directly. The award vests over time: 25% of the shares are scheduled to vest on November 15, 2026, and the remaining 75% vest in equal quarterly installments over three years on 2/15, 5/15, 8/15, and 11/15, aligning his compensation with longer-term company performance.
Omnicell, Inc. (OMCL) reported an insider equity transaction involving an executive advisor. On 11/15/2025, 7,368 shares of common stock were withheld at a price of $35.12 per share to cover taxes due on the vesting of restricted stock units. After this tax withholding, the reporting person beneficially owned 117,808 shares of Omnicell common stock directly. The filing notes that the transaction may have been executed under a Rule 10b5-1 trading plan.
Omnicell, Inc. executive reports routine stock transactions. The EVP and Chief Legal/Administrative Officer reported two transactions in Omnicell common stock. On 11/15/2025, 2,792 shares were withheld to cover taxes due on vesting of restricted stock units at a price of $35.12 per share, leaving 107,861 shares beneficially owned. On 11/17/2025, the executive sold 3,473 shares at an exact price of $34.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, resulting in 104,388 shares beneficially owned after the sale. The filing is made by one reporting person.
Omnicell reported Q3 2025 results, with total revenue of $310.6 million, up from $282.4 million a year ago. Product revenue was $177.5 million and service revenue was $133.1 million. Net income was $5.5 million, or $0.12 per diluted share, versus $8.6 million, or $0.19, last year as operating expenses rose.
For the first nine months, revenue reached $870.9 million with net income of $4.1 million. Cash from operations was $96.9 million. The company ended the quarter with $180.1 million in cash and cash equivalents. Omnicell repaid the remaining $175.0 million principal of its 0.25% convertible notes due 2025 and had $167.3 million (net) outstanding on the 1.00% notes due 2029. Deferred revenues were $245.5 million, including $178.8 million current.
Stockholders’ equity was $1.22 billion. The company repurchased common stock totaling $77.6 million year‑to‑date, and shares outstanding were 44,876,522 as of October 29, 2025.
Omnicell, Inc. furnished an update on performance, announcing third-quarter 2025 financial results and an update to full-year 2025 guidance via a press release. The company provided the details in Exhibit 99.1, referenced under Item 2.02 of the report. The information in Item 2.02 and Exhibit 99.1 is being furnished and not filed under the Exchange Act.
Dimensional Fund Advisors LP filed a Schedule 13G reporting beneficial ownership of 2,364,068 shares of Omnicell Inc. Common Stock, representing 5.1% of the class. Dimensional states these shares are owned by mutual funds, commingled funds, group trusts and separate accounts for which it serves as investment adviser or sub-adviser, and it disclaims beneficial ownership while reporting its voting and dispositive powers: 2,303,090 shares of sole voting power and 2,364,068 shares of sole dispositive power. The filing confirms the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Omnicell, Inc. filed an 8-K to report that its board of directors adopted the company’s Fourth Amended and Restated Bylaws, effective September 30, 2025. The updated bylaws refine how shareholders can nominate directors and submit proposals at annual and special meetings, adding more detailed disclosure requirements for nominating or proposing shareholders, their nominees, and any individuals behind entity shareholders. The revisions also address matters related to Rule 14a-19 of the Exchange Act, clarify the company’s forum and personal jurisdiction provisions for certain lawsuits, and make various ministerial and conforming changes.
Corey J. Manley, Executive Vice President & Chief Legal/Administrative Officer of Omnicell, Inc. (OMCL), reported a sale of 3,880 shares of Omnicell common stock on 09/12/2025 at a price of $33.25 per share. After the transaction, Mr. Manley beneficially owned 110,653 shares, held directly. The filing notes the sale was made pursuant to a pre-established Rule 10b5-1 trading plan adopted on June 13, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Manley on 09/16/2025.
Omnicell, Inc. (OMCL) Form 3 filed for Radford Harlan Baird, who is listed as an Officer (EVP & Chief Financial Officer) and director-level reporting person. The statement, tied to the 08/26/2025 event date, reports no securities beneficially owned by the reporting person. The filing is signed by an attorney-in-fact on 09/05/2025 and attaches a power of attorney as Exhibit 24.